Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1335-1341

  Beauclair, S ^a   Formento, P ^a   Fischel, J L ^a   Lescaut, W ^a   Largillier, R ^a   Chamorey, E ^a   Hofman, P ^b   Ferrero, J M ^a   Pages G ^c   Milano, G ^a,d  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSERM   (France)

^c CENTRE DE BIOCHIMIE   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Cardiotoxicity; Gene polymorphism; HER 2; Trastuzumab

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOLEUCINE; PACLITAXEL; TRASTUZUMAB; VALINE;

ADJUVANT THERAPY; ADULT; AGED; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; DRUG SENSITIVITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TUMOR GROWTH;

EID: 34548179576     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm181     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. De Laurentiis M, Cancello G, Zinno L et al. Targeting HER2 a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005; 16 (Suppl 4): Iv7-iv13.
3. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642-1646.
4. Frank B, Hemminid K, Wirtenberger M et al. The rare ERBB2 variant lle654Val is associated with an increased familial breast cancer risk. Carcinogenesis 2005; 26: 643-647.
5. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99: 15937-15940.
6. Xie D, Shu XO, Deng Z et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-417.
7. Benusiglio PR, Lesueur F, Luccarini C et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: A case-control study. Breast Cancer Res 2005; 7: R204-209.
8. An HJ, Kim NK, Oh D et al. Her2 genotype and breast cancer progression in Korean women. Pathol Int 2005; 55: 48-52.
9. Wang-Gohrke S, Chang-Claude J. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93: 1657-1659.
10. Millikan RC, Hummer AJ, Wolff MS et al. HER2 codon 655 polymorphism and breast cancer: Results from kin-cohort and case-control analyses. Breast Cancer Res Treat 2005; 89: 309-312.
11. Milanini J, Vinals F, Pouysségur J et al. p42/p44 MAP Kinase module plays a key role in the transcriptional regulation of vascular endothellal growth factor gene in fibroblasts. J Biol Chem 1998; 273: 18165-18172.
12. Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-2171.
13. Agus DB, Scher HI, Higgins B et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999; 59: 4761-4764.
14. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
15. Marchetti S, Gimond C, Roux D et al. Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice. J Cell Physiol 2004; 199: 441-450.
16. Hishida A, Hamjima N, Iwata H et al. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2002; 94: 1807-1808.
17. Baxter SW, Campbell IG. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93: 557-559.
18. Stortelers C, van der Woning SP, Jacobs-Oomen S et al. Selective formation of ErbB-2/ErbB-3 heterodlmers depends on the ErbB-3 affinity of epidermal growth factor-like ligands. J Biol Chem 2003; 278: 12055-12063.
19. Garrett TP, McKern NM, Lou M et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11: 495-505.
20. Han W, Kang D, Lee JE et al. A haplotype analysis of HER-2 gene polymorphisms: Association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin Cancer Res 2005; 11: 4775-4778.
21. Nagata Y, Lan KH, Zhoux et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
22. Albanell J, Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a now suspect. J Natl Cancer Inst 2001; 93: 1830-1832.
23. Levíne MN. Trastuzumab cardiac side effects: Only time will tell. J Clin Oncol 2005; 23: 7775-7776.
24. Floyd JD, Nguyen DT, Lobins RL et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005; 23: 7685-7696.
25. Ueda H, Oikawa A, Nakamura A et al. Neuergulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle. J Histochem Cytochem 2005; 53: 87-91.
26. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
27. Piccart-Gabhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
28. Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin(R) in adjuvant setting: The Breast Cancer International Research Group 006 trial. Ann Oncoll 2006; 17: 381-390.